A Phase 1b Study of Lenvatinib plus Nivolumab in Patients with Unresectable Hepatocellular Carcinoma - PubMed
4 hours ago
- #Lenvatinib
- #Nivolumab
- #Hepatocellular carcinoma
- Phase 1b study evaluates lenvatinib + nivolumab in unresectable hepatocellular carcinoma (uHCC).
- Study conducted in Japan with adults (≥20 years) with confirmed HCC.
- Patients received lenvatinib (8 mg or 12 mg daily) + nivolumab (240 mg every 2 weeks).
- No dose-limiting toxicities (DLTs) observed in part 1 (n=6).
- Treatment-related adverse events (TRAEs) occurred in all patients (n=30), most common being palmar-plantar erythrodysesthesia (60%).
- Objective response rate (ORR) was 66.7% (part 1) and 79.2% (part 2) by mRECIST.
- Median progression-free survival (PFS) was 9.07 months, and median overall survival (OS) was 26.94 months in part 2.
- Lenvatinib + nivolumab was well-tolerated and showed promising antitumor activity in advanced uHCC.